Category: News & Comments
Seattle Genetics' Agreement with Immunomedics: The Benefit Vs. the Risk
Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to develop, fund, manufacture, and commercialize Immunomedics' solid tumor drug candidate IMMU-132 . Seattle Genetics accepted to take the responsibility for initiating Phase 3 clinical...
Read More
February 14, 2017
0
Interpreting Portola Pharmaceuticals' News
The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not plan to hold an Advisory Committee meeting for its Product betrixaban . What is betrixapan? Betrixapan is a small molecule oral, once-daily, Factor Xa...
Read More
February 9, 2017
0
Companies Targeted for Takeover Yet Can Thrive on their Own
It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become...
Read More
February 2, 2017
0
Welcoming Jounce Therapeutics (JNCE) as a Public Company
Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE) . The Company, which focuses on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the pricing of its initial public offering of...
Read More
January 22, 2017
0
Vertex and Merck KGaA Agreement Suits Both Firms
Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four research and development programs that the firm believes represent novel approaches to cancer treatment Merck KGaA will license two clinical-stage...
Read More
January 13, 2017
0
Takeda Acquires Ariad for $5.2 Billion
ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in...
Read More
January 9, 2017
0
Halozyme's PEGPH20 Trial Results Are Worth Appreciating Not Doubting
Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center clinical trial of its PEGPH20 in combination with ABRAXANE ® (nab-paclitaxel) and gemcitabine in stage IV pancreas cancer. The results demonstrated a statistically significant...
Read More
January 6, 2017
0
Dana-Farber Institute and Array Pharmaceutical Scientists to Work Together
Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications. Who are these people, meaning Danna-Faber Cancer institute ? Founded in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has...
Read More
February 2, 2016
0
Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm
Gilead Sciences Gilead (GILD) Shareholders wouldn’t expect to watch short investors make billions of dollars going against Gilead during this firm's most glorious times. We never imagined negative analysts could have the capability of persuading millions of shareholders to sell...
Read More
February 5, 2016
0
Regulus Offers Proof of Concept and Feasibility with Its HCV RNA Targeted Drug
Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one of the company's ongoing Phase 2 studies of its hepatitis C virus (HCV) product RG-101. The study was designed to evaluate...
Read More
February 17, 2016
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)